FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/21/2022
Back to search
Official data from USPTO
CURIGIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CURIGIN
ST13
US500000079288213Class
5, 35, 42, 44
Filing
79288213
Registration
6585328
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
06/21/2022
Trademark type
Word
Nice classes
5, 35, 42, 44
Filing date
04/21/2020
Registration date
12/14/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/14/2021
Last transaction
12/14/2021
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
KR
Examiner
BRADLEY, EVELYN
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Curigin Co., Ltd
Representatives
Eric S. Hyman Womble Bond Dickinson (US) LLP
Technical classification
Nice Classes
Class 5Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biopharmaceuticals for the prevention of cancer; biopharmaceuticals for the diagnosis of cancer; biopharmaceuticals for the treatment of cancer; biopharmaceuticals in the form of cancer oncolytic virus for the prevention of cancer; biopharmaceuticals in the form oncolytic virus for the diagnosis of cancer; biopharmaceuticals in the form of oncolytic virus for the treatment of cancer; Drugs for medical purpose for the treatment of cancer and non-cancerous diseasesrespiratorymetabolicneurologicalophthalmologicalgastrointestinalcardiovascularskinurogenitalgynecologicalendocrinehead and neckskeletalautoimmune and rare diseases; Veterinary preparations for the treatment of cancer and non-cancerous diseasesrespiratorymetabolicneurologicalophthalmologicalgastrointestinalcardiovascularskinurogenitalgynecologicalendocrinehead and neckskeletalautoimmune and rare diseases; anti-cancer preparations; antiulcerants; vaccines; pharmaceutical preparations and substances for the prevention of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of cancer; viral and non-viral vector-based pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical compounds for treating cancer; pharmaceuticals for viral and non-viral vector-based gene therapy; medicine for viral and non-viral vector-based gene therapy for human purposes; antibiotics; dietary supplements; dietetic nutritionally fortified food adapted for medical purposes; insecticides; fungicides
Class 35
Providing commercial information and consumer product information; import-export agency services; sales agency servicessales promotion for others in the field of apparatus for use in medical analysis; arranging sales events for others in the field of apparatus for use in medical analysis; sales agency servicessales promotion for others in the field of pharmaceuticals; arranging sales events for others in the field of pharmaceuticals; business intermediary services in the nature of purchasing pharmaceuticals for others relating to mail order by telecommunications; procurement of contracts for the purchase and sale of goods and services; advertising services; advertising services relating to pharmaceutical products; business intermediary services in the nature of matching purchasers with sellers of goods and services for the sale and purchase of goods and services
Class 42
Research relating to biotechnology; scientific research for medical purposes in the field of cancerous diseases; research relating to pharmaceuticals; research in the field of medical products; medical research services; conducting clinical trials for others; clinical studies in the nature of medical research; development of new technology for others in the field of biotechnology; scientific research for medical purposes in the area of cancerous diseases; development of medical products; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; conducting clinical research in the field of medicines; clinical trials of medicinesfor others; software design and development; computer programming for others in the medical field
Class 44
Providing health informationnot including dentistry; healthcare information services relating to the use of medical products for the preventiondiagnosis and treatment of cancer and non-cancerous diseases; medical and pharmaceutical consultancy; consultancy services relating to pharmaceutical products for the preventiondiagnosis and treatment of cancer and non-cancerous diseases; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceutical products for the preventiondiagnosis and treatment of cancer and non-cancerous diseases
Publications
History of USPTO decisions and trademark events.
37 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/25/2022
FIMP
FINAL DISPOSITION PROCESSED
05/24/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/14/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/19/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
12/14/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/01/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/01/2021
GPNX
NOTIFICATION PROCESSED BY IB
10/25/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/28/2021
PUBO
PUBLISHED FOR OPPOSITION
09/28/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/22/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/22/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/08/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/25/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
08/25/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/25/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
08/25/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/25/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/09/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/09/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/09/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
04/08/2021
GNFR
FINAL REFUSAL E-MAILED
04/08/2021
CNFR
FINAL REFUSAL WRITTEN
04/08/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/25/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/25/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/25/2021
RFNT
REFUSAL PROCESSED BY IB
09/27/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/05/2020
RFRR
REFUSAL PROCESSED BY MPU
08/25/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/19/2020
CNRT
NON-FINAL ACTION WRITTEN
07/18/2020
DOCK
ASSIGNED TO EXAMINER
07/13/2020
MAFR
APPLICATION FILING RECEIPT MAILED
06/30/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/26/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/25/2020
Continuous trademark protection
Get notified about every new filing that threatens CURIGIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.